Clinical Trials Browser

INDUSTRY × Has announcements × Sorafenib × Clear all

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03298451 2026-03-20

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03434379 2023-10-23

IMbrave150

Phase 3 Completed

558 enrolled 48 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT02627963 2023-07-18

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

Phase 3 Completed

350 enrolled 14 charts 1 FDA

Carcinoma, Renal Cell

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms